Research & Development

Can Lorundrostat Revolutionize Treatment for Resistant Hypertension?
Research & Development Can Lorundrostat Revolutionize Treatment for Resistant Hypertension?

Resistant hypertension affects more than half of patients suffering from high blood pressure, presenting a significant challenge for healthcare providers. This condition often remains uncontrolled by multiple medications, typically linked to elevated levels of aldosterone, a hormone regulating

Funding Freeze Halts Crucial Malaria Vaccine Trials Amidst Global Needs
Research & Development Funding Freeze Halts Crucial Malaria Vaccine Trials Amidst Global Needs

The recent halt of life-saving drug trials due to an unanticipated funding freeze by the U.S. government has created significant uncertainty and disruption in the fight against malaria, a disease that remains a major global health threat. This decision, stemming from an initiative by the Trump

Is the FDA Allowing Unsafe Additives in America's Food Supply?
Research & Development Is the FDA Allowing Unsafe Additives in America's Food Supply?

The oversight practices of the Food and Drug Administration (FDA) regarding food additives and substances have come under scrutiny. This article explores the FDA's regulation of food safety, the autonomy granted to food companies, and the health risks associated with certain ingredients,

Are VA Hospitals in Crisis Due to DOGE Budget Cuts and Firings?
Research & Development Are VA Hospitals in Crisis Due to DOGE Budget Cuts and Firings?

Ivan Kairatov is a Biopharma expert with a wealth of knowledge in tech and innovation within the industry, bolstered by extensive experience in research and development. Today's interview will delve into the impact of recent administrative changes on VA hospitals, specifically examining the role of

FDA Grants Orphan Drug Designation to Bexmarilimab for MDS Treatment
Research & Development FDA Grants Orphan Drug Designation to Bexmarilimab for MDS Treatment

On March 3, 2025, Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focusing on targeting the CLEVER-1 receptor to reprogram myeloid cells for anti-tumor immunity in both hematological and solid tumors, announced a significant milestone. Their lead therapeutic candidate,

New Cancer Drugs Show Potential to Surpass Keytruda in Clinical Trials
Research & Development New Cancer Drugs Show Potential to Surpass Keytruda in Clinical Trials

The pharmaceutical industry is abuzz with excitement over a new class of cancer drugs known as PD-1/VEGF inhibitors. These promising therapies, currently undergoing clinical trials, might leapfrog Merck & Co.’s highly successful cancer immunotherapy, Keytruda. The advent of these new drugs could

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later